跳至主要内容
临床试验/NCT01473251
NCT01473251已完成不适用

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

Vitreo-Retinal Associates, Michigan1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
16
试验地点
1
主要终点
Analysis of collected vitreous samples to identify biomarkers.

研究概览

简要总结

The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female age 18 to 85 with diabetes and hemoglobin A1C </= 10, or exudative macular degeneration.
  • Diabetic macular edema with average retinal thickness central subfield >/= 290um.

排除标准

  • Macular atrophy/fibrosis.
  • Ocular anti-VEGF treatment within 3 months.
  • Treatment with topical or oral carbonic-anhydrase inhibitor within one month
  • Laser photocoagulation within 3 months (diabetic cohort)

研究组 & 干预措施

Avastin for Diabetic Macular Edema

Active Comparator

1.25 mg avastin monthly for 4 months

干预措施: Avastin (Drug)

Avastin for Exudative Macular Degeneration

Active Comparator

1.25 mg Avastin monthly for 4 months

干预措施: Avastin (Drug)

Lucentis for Exudative Macular Degeneration

Active Comparator

0.5 mg Lucentis monthly for 4 months

干预措施: Lucentis (Drug)

结局指标

主要结局

Analysis of collected vitreous samples to identify biomarkers.

时间窗: End of study

Analysis of collected vitreous samples in regards to identification of biomarkers that are prognostic for response to anti-angiogenic treatment of retinopathy, and the exploration of a more effective dosing regiment for intravitreal injections of Lucentis/Avastin for exudative macular degeneration and Avastin for diabetic macular edema.

次要结局

未报告次要终点

研究者

发起方
Vitreo-Retinal Associates, Michigan
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验